Retinopathy of Prematurity
Conditions
Keywords
Retinopathy of Prematurity, ROP
Brief summary
This is an open-label, single-arm phase I/II trial to evaluate the safety and efficacy of Rho-associated protein kinase(ROCK) inhibitor Ripasudil eye drops for preterm infants with Retinopathy of Prematurity(ROP).
Detailed description
Ripasudil eye drops will be administrated to all enrolled preterm infants with zone I/II stage 1 or greater ROP （except for aggressive posterior ROP, Type1 ROP ）. The safety and efficacy of ripasudil in treated patients will be assessed in comparison to a historical control.
Interventions
DRUGRipasudil ophthalmic solution 0.4%
Phase1 A total of three infants will receive ripasudil eye drops(0.4%) once daily for one week, followed by twice-daily drug administration for two weeks. The three infants who participate in Phase1 can continue to receive the eye drop treatment for additional 9 weeks(12 weeks in total)if the investigators determine that there are no safety issues with ripasudil. In addition, a data and safety monitoring board(DSMB)will be held two times to decide whether the new patients can be enrolled into phase1, and also if phase2 can begin. Phase2:A total of 21 patients will receive ripasudil eye drops(0.4%)twice daily for 12 weeks.
Sponsors
Kyushu University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 4 Months
Healthy volunteers
No
Inclusion criteria
* 1\. Informed consent signed by parents or legal guardians of the patient * 2\. Patients born with less than or equal to 32 weeks of gestational age and/or less than or equal to 1,500 grams of birth weight * 3\. Patients with the following types of ROP in both eyes 1. Zone I ROP with stage greater than or equal to 1 2. Zone II ROP with stage greater than or equal to 1
Exclusion criteria
* 1\. Patients with aggressive posterior ROP in one or both eyes * 2\. Patients with type 1 ROP in one or both eyes * 3\. Patients with a confirmed or suspected chromosomal abnormality or genetic disorder * 4\. History of hypersensitivity to ripasudil (including drugs with similar chemical structure) in patients or their mothers * 5\. Patients or their mothers have participated in another intervention study and have used the study drug of another intervention study within 30 days prior to enrollment in this study or within 5 times the half-life of the study drug * 6\. Patients with an ocular structural abnormality that can affect the evaluation of this clinical study by investigators * 7\. Patients with a clinically significant neurological disease (e.g., intraventricular hemorrhage grade 3 or higher, severe hydrocephalus with significantly increased intracranial pressure) * 8\. Patients with inadequate blood access * 9\. Patients with complications, allergies, or worsening systemic conditions that make it difficult to conduct this trial * 10\. Patients judged unsuitable by investigators
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with Adverse Events(AEs) and Adverse Drug Reactions(ADRs) | throughout the study duration(up to week16) | Safety Assessment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients whose ROP worsens to Type1 ROP in one or both eyes | week12 of treatment | Efficacy Assessment： ripasudil-treated patients will be assessed in comparison to the medical records of a historical control group |
| Proportion of patients with ROP remission in both eyes | week12 of treatment | Efficacy Assessment： ripasudil-treated patients will be assessed in comparison to the medical records of a historical control group |
| Concentration of ripasudil and its metabolite M1 | throughout the study duration(up to week12) | Pharmacokinetics, the population pharmacokinetic(popPK) |
Countries
Japan
Outcome results
None listed